– USA, MO – Geneoscopy, a life sciences company focused on developing diagnostic tests for gastrointestinal health, announced the appointment of Don Hardison as Chairman of its Board of Directors.
“As an accomplished and respected executive in our industry, Don’s expertise and insights will be invaluable in helping steer our efforts to bring innovative, noninvasive diagnostics for gastrointestinal health to the providers and individuals who will benefit the most,” said CEO, Andrew Barnell.
About Don Hardison
With a career spanning over 40 years in executive leadership roles in emerging and Fortune 500 diagnostics, biotechnology, and life sciences companies, Don Hardison brings a wealth of experience and expertise to Geneoscopy as the company moves toward commercialization of its noninvasive, multi-target, stool RNA colorectal cancer screening test.
Having previously served as a strategic advisor to Geneoscopy before joining the board in February 2023, Don Hardison is well-acquainted with the company’s vision and strategy. In his expanded role as Chairman of the Board, he will provide insight and guidance as Geneoscopy prepares to commercialize its flagship product – ColoSense™, a noninvasive, stool-based, at-home screening test designed to detect colorectal cancer and advanced adenomas in average-risk individuals. Geneoscopy submitted a Premarket Approval application to the U.S. Food and Drug Administration for this test based on the favorable results from the pivotal CRC-PREVENT trial recently published in JAMA.
“As an advisor and board member, I have been impressed by what Geneoscopy has accomplished, and I’m honored to assume the role of Chairman of the Board at Geneoscopy during this exciting inflection point for the company,” said Don Hardison. “As we move forward, my primary focus will be supporting Geneoscopy’s talented leadership team by helping to guide its commercialization strategies, advance the company’s development, and drive its growth in gastrointestinal diagnostics.”
His notable career includes serving as the President and CEO of Biotheranostics until its acquisition by Hologic in February 2021, where he played a significant role in the company’s success. Before that, he held the positions of President, CEO, and Director at Good Start Genetics. Hardison’s experience extends to his tenure as President and CEO of Exact Sciences from 2000 to 2007, where he was instrumental in taking the company public. He also held multiple senior leadership positions at Labcorp, Quest Diagnostics, and SmithKline Beecham.
About Geneoscopy, Inc.
Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA biomarker platform, Geneoscopy’s mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Beyond colorectal cancer screening, Geneoscopy is developing tests for diagnosis, treatment selection, and therapy monitoring in other disease areas in partnership with leading universities and biopharmaceutical companies.
SOURCE: https://www.geneoscopy.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
